AMC Entertainment price target raised to $3.25 from $2.50 at B. Riley
B. Riley raised AMC Entertainment's price target to $3.25 from $2.50, maintaining a Neutral rating. Disc Medicine's stock surged 37.24% after positive Phase 3 trial results for bitopertin, with analysts giving a Strong Buy consensus and $110.22 price target.
How this was made
The 30-second read
Why it matters
The price target increase signals a modest bullish view but retains a Neutral rating, suggesting limited upside.
Market read
Analyst price target updates are a common catalyst for short-term trading decisions.
What to watch
Upcoming Q3 earnings could confirm or reverse the new target.
Background
AMC is a publicly traded theater chain; analyst coverage influences price expectations.
Ticker impact
B. Riley raised AMC's price target to $3.25 from $2.50 and kept a Neutral rating.
likely upward pressure as investors price in higher target
New target reflects improved outlook; no immediate catalyst but could attract buyers.
Market effects
May slightly boost theater and entertainment sector sentiment.
U.S. market focus, limited broader impact.
Low global relevance.
Counterpoint
Target raise could be premature if earnings disappoint.
Key entities
- AnalystB. Riley
Equity research firm that issued the new price target.




